<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/">
<rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/7124">
    <dcterms:title><![CDATA[<strong>New Cu complexes containing methyl-phenanthroline and dipeptides as cytotoxic agents: synthesis, characterization and in vitro studies</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[COMPLEJOS DE COBRE]]></dcterms:subject>
    <dcterms:subject><![CDATA[ACTIVIDAD CITOTOXICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[CANCER]]></dcterms:subject>
    <dcterms:subject><![CDATA[TRATAMIENTO]]></dcterms:subject>
    <dcterms:subject><![CDATA[DIFRACCION DE RAYOS X]]></dcterms:subject>
    <dcterms:subject><![CDATA[FENANTROLINA]]></dcterms:subject>
    <dcterms:subject><![CDATA[ADN]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2026]]></dcterms:subject>
    <dcterms:abstract><![CDATA[The high incidence and mortality associated with cancer evidence the need for novel therapeutic agents. Metalbased coordination compounds offer a diverse arsenal of molecules that can be developed into drugs, beyond those currently in clinical use. Among them, copper complexes are emerging as promising candidates for cancer treatment. In this study, a series of complexes [Cu(L-dipeptide)(met-phen)] (where met-phen: 4-methyl-1,10- phenanthroline and 5-methyl-1,10-phenanthroline) were synthesized and characterized. Solid-state characterization included the determination of the crystal structures of [Cu(Gly-Gly)(4met-phen)]⋅5.5 H2O and [Cu(pheala)( 4met-phen)]⋅3H2O. DNA binding was assessed through the intrinsic binding constant (Kb) and relative viscosity measurements, indicating partial intercalation into calf-thymus DNA. The obtained Kb values were approximately tenfold lower than those reported for analogous complexes with phenanthroline. The cytotoxicity of the complexes was evaluated against a panel of human cancer cell lines: metastatic breast adenocarcinoma MDA-MB-231 (triple negative, ATCC: HTB-26), lung epithelial carcinoma A549 (ATCC: CCL-185), ovarian carcinoma A2780 (ECACC 93112519), and nontumoral lung cell line MRC-5 (ATCC: CCL-171). The complexes exhibited potent cytotoxicity, with IC₅₀ values in the low micromolar range, which was significantly more effective than that of cisplatin. [Cu(ala-gly)(5met-phen)] inhibits clonogenic colony formation and induces cellular death above its IC₅₀. These findings evidence that [Cu(L-dipeptide)(met-phen)] complexes are interesting candidates for further in vivo investigation.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?14542fe9058bf79fe6b16bbd23c1096e"><strong>Brooks, Lirka</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Palmeira-Mello, Marcos V</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?6ff98e50c61daf2fd24006b2cb221c82"><strong>Fernandez, Carlos Y.</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Arandia, Inés</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Ellena, Javier</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Costa-Filho, Antonio J</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Batista, Alzir A</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Alvarez, Natalia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?a41bd5cdd282cee0c5c8be3585cd7593514fcf7fb722e1194e086a5aa98159780502b217d616fd5bb450c02a6152253b7a8957278f35e3a01aabdd446a54f376"><strong>Facchin, Gianella</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Journal of Inorganic Biochemistry, v. 274, 2026. -- e113089]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2026]]></dcterms:date>
    <dcterms:rights><![CDATA[<strong>Información sobre Derechos de Autor</strong><br /><br />(Por favor lea este aviso antes de abrir los documentos u objetos)<br /><br /><strong>La legislación uruguaya protege el derecho</strong> de autor sobre toda creación literaria, científica o artística, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeción a lo establecido por el derecho común y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006) <br /><br /><strong>ADVERTENCIA</strong> - La consulta de este documento queda condicionada a la aceptación de las siguientes condiciones de uso: Este documento es únicamente para usos privados enmarcados en actividades de investigación y docencia. No se autoriza su reproducción con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilización o cita de partes debe indicarse el nombre de la persona autora]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:extent><![CDATA[10 p.]]></dcterms:extent>
    <dcterms:language><![CDATA[Inglés]]></dcterms:language>
    <dcterms:type><![CDATA[Artículo]]></dcterms:type>
    <dcterms:identifier><![CDATA[10.1016/j.jinorgbio.2025.113089]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6681">
    <dcterms:title><![CDATA[<strong>Development of copper complexes with diimines and cipicolinate as anticancer cytotoxic agents</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[COMPLEJOS DE COBRE]]></dcterms:subject>
    <dcterms:subject><![CDATA[FENANTROLINA]]></dcterms:subject>
    <dcterms:subject><![CDATA[ACTIVIDAD CITOTOXICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[NEOCUPROINA]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2023]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Coordination complexes may act as anticancer agents. Among others, the formation of the complex may facilitate the ligand uptake by the cell. Searching for new copper compounds with cytotoxic activity, the complex Cu-dipicolinate was studied as a neutral scaffold to form ternary complexes with diimines. A series of [Cu(dipicolinate)(diimine)] complexes (where diimine: Phenan throline, phen, 5-NO2 -phenanthroline, 4-methyl-phenanthroline, neocuproine, 3,4,7,8-tetramethyl phenanthroline, tmp, bathophenanthroline, bipyridine, dimethyl-bipyridine, as well as the ligand 2,2-dipyridil-amine, bam) were synthesized and characterized both in the solid state, including a new crystal structure of [Cu2 (dipicolinate)2 (tmp)2 ]&middot;7H2O. Their chemistry in aqueous solution was explored by UV/vis spectroscopy, conductivity, cyclic voltammetry, and electron paramagnetic resonance studies. Their DNA binding was analyzed by electronic spectroscopy (determining Kb values), circular dichroism, and viscosity methods. The cytotoxicity of the complexes was assessed on human cancer cell lines MDA-MB-231, MCF-7 (breast, the first triple negative), A549 (lung epithelial) and A2780cis (ovarian, Cisplatin-resistant), and non-tumor cell lines MRC-5 (lung) and MCF-10A (breast). The major species are ternary, in solution and solid state. Complexes are highly cytotoxic as compared to Cisplatin. Complexes containing bam and phen are interesting candidates to study their in vivo activity in triple-negative breast cancer treatment.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?e635b6babb330f7d853c44bebf28147f45249ebe02a83f148a2cc7d1d4cfc6eb7c052c905498e0db71ce84c545c5bc262c0c1fa15dd485e385d82024819cf422" target="_blank"><strong>Alvarez, Natalia</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Rocha, Analu</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?7137e9ec5123825148e3f0f298c66868" target="_blank"><strong>Collazo, Victoria</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Ellena, Javier</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Costa Filho, Antonio J.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Batista, Alzir A.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?a41bd5cdd282cee0c5c8be3585cd7593514fcf7fb722e1194e086a5aa98159780502b217d616fd5bb450c02a6152253b7a8957278f35e3a01aabdd446a54f376" target="_blank"><strong>Facchin, Gianella</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Pharmaceutics, v.15, n&deg;5, 2023.]]></dcterms:source>
    <dcterms:publisher><![CDATA[MDPI]]></dcterms:publisher>
    <dcterms:date><![CDATA[2023]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong>&nbsp;de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:extent><![CDATA[18 p.]]></dcterms:extent>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[10.3390/pharmaceutics15051345]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6619">
    <dcterms:title><![CDATA[<strong>New Copper(II)-L-Dipeptide-Bathophenanthroline complexes as potential anticancer agents&mdash;synthesis, characterization and cytotoxicity studies&mdash;and comparative DNA-Binding study of related phen complexes</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[COMPLEJOS DE COBRE]]></dcterms:subject>
    <dcterms:subject><![CDATA[PEPTIDOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ADN]]></dcterms:subject>
    <dcterms:subject><![CDATA[ACTIVIDAD CITOTOXICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[FENANTROLINA]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2023]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Searching for new copper compounds which may be useful as antitumor drugs, a series of new [Cu(L-dipeptide)(batho)] (batho:4,7-diphenyl-1,10-phenanthroline, L-dipeptide: Gly-Val, Gly Phe, Ala-Gly, Ala-Ala, Ala-Phe, Phe-Ala, Phe-Val and Phe-Phe) complexes were synthesized and characterized. To interpret the experimental IR spectra, [Cu(ala-gly)(batho)] was modelled in the gas phase using DFT at the B3LYP/LANL2DZ level of theory and the calculated vibrational frequencies were analyzed. Solid-state characterization is in agreement with pentacoordinate complexes of the general formula [Cu(L-dipeptide)(batho)]&middot;x solvent, similar to other [Cu(L-dipeptide)(diimine)] complexes. In solution, the major species are heteroleptic, as in the solid state. The mode of binding to the DNA was evaluated by different techniques, to understand the role of the diimine and the dipeptide. To this end, studies were also performed with complexes [CuCl2 (diimine)], [Cu(L dipeptide)(diimine)] and free diimines, with phenanthroline, neocuproine and 3,4,7,8-tetramethyl phenanthroline. The cytotoxicity of the complexes was determined on human cancer cell lines MDA-MB-231, MCF-7 (breast, the first triple negative), and A549 (lung epithelial) and non-tumor cell lines MRC-5 (lung) and MCF-10A (breast). [Cu(L-dipeptide)(batho)] complexes are highly cytotoxic as compared to cisplatin and [Cu(L-dipeptide)(phenanthroline)] complexes, being potential candidates to study their in vivo activity in the treatments of aggressive tumors for which there is no curative pharmacological treatment.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?6ff98e50c61daf2fd24006b2cb221c82" target="_blank"><strong>Fern&aacute;ndez, Carlos Y.</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?e635b6babb330f7d853c44bebf28147f45249ebe02a83f148a2cc7d1d4cfc6eb7c052c905498e0db71ce84c545c5bc262c0c1fa15dd485e385d82024819cf422" target="_blank"><strong>Alvarez, Natalia</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Rocha, Analu</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Ellena, Javier</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Costa Filho, Antonio J.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Batista, Alzir A.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?a41bd5cdd282cee0c5c8be3585cd7593514fcf7fb722e1194e086a5aa98159780502b217d616fd5bb450c02a6152253b7a8957278f35e3a01aabdd446a54f376" target="_blank"><strong>Facchin, Gianella</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Molecules v.28, n&deg;2, 2023]]></dcterms:source>
    <dcterms:publisher><![CDATA[MDPI]]></dcterms:publisher>
    <dcterms:date><![CDATA[2023]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong>&nbsp;de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:extent><![CDATA[14 p.]]></dcterms:extent>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[10.3390/molecules28020896]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6533">
    <dcterms:title><![CDATA[<strong>Tetramethyl-phenanthroline copper complexes in the development of drugs to treat cancer: synthesis, characterization and cytotoxicity studies of a series of copper(II)-L-dipeptide-3,4,7,8-tetramethyl-phenanthroline complexes</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[COMPLEJOS DE COBRE]]></dcterms:subject>
    <dcterms:subject><![CDATA[PEPTIDOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[FENANTROLINA]]></dcterms:subject>
    <dcterms:subject><![CDATA[DIFRACCION DE RAYOS X]]></dcterms:subject>
    <dcterms:subject><![CDATA[ADN]]></dcterms:subject>
    <dcterms:subject><![CDATA[ACTIVIDAD CITOTOXICA]]></dcterms:subject>
    <dcterms:abstract><![CDATA[New compounds to fght cancer are needed due to cancer high incidence and lack of curative treatments for several classes of this disease. Metal-based coordination compounds ofer a variety of molecules that can turn into drugs. Among them, coordi nation copper complexes are emerging as an attractive class of compounds for cancer treatment. A series of [Cu(l-dipeptide) (tmp)] (tmp=3,4,7,8-tetramethyl-1,10-phenanthroline) complexes were synthesized and characterized in the solid state, including the determination of the crystalline structure of [Cu(Gly-Gly)(tmp)]&middot;3.5 H2O and [Cu2Cl4(tmp)2]. The complexes were studied in solution, where the major species are also ternary ones. The lipophilicity of the complexes was determined and the binding to the DNA was evaluated, suggesting that it occurs in the DNA&rsquo;s major groove. The cytotoxicity of the com plexes was evaluated on diferent cancer cell lines: human metastatic breast adenocarcinoma MDA-MB-231 (triple negative, ATCC: HTB-26), MCF-7 (ATCC: HTB-22), SK-BR-3 (ATCC: HTB-30), human lung epithelial carcinoma A549 (ATCC: CCL-185), cisplatin resistant-human ovarian carcinoma A2780cis (SIGMA) and nontumoral cell lines: MRC-5 (lung; ATCC: CCL-171) and MCF-10A (breast, ATCC: CRL-10317). [Cu(l-dipeptide)(tmp)] complexes are highly cytotoxic as compared to [Cu(l-dipeptide)(phenanthroline)] and cisplatin. Therefore, [Cu(l-dipeptide)(tmp)] complexes are promising candidates to have their in vivo activity further studied toward new treatments for triple negative breast cancer and other aggressive tumors for which there is no curative pharmacological treatment to the date.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<a href="https://exportcvuy.anii.org.uy/cv/?e635b6babb330f7d853c44bebf28147f45249ebe02a83f148a2cc7d1d4cfc6eb7c052c905498e0db71ce84c545c5bc262c0c1fa15dd485e385d82024819cf422" target="_blank"><strong>Alvarez, Natalia&nbsp;</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Leite, Celisnolia M.&nbsp;</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Napoleone, Adriana&nbsp;</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Mendes, Luis F. S.&nbsp;</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://exportcvuy.anii.org.uy/cv/?6ff98e50c61daf2fd24006b2cb221c82" target="_blank"><strong>Fern&aacute;ndez, Carlos Y.&nbsp;</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Ribeiro, Ronny R.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Ellena, Javier&nbsp;</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Batista, Alzir A.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Costa Filho, Antonio J.&nbsp;</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://exportcvuy.anii.org.uy/cv/?a41bd5cdd282cee0c5c8be3585cd7593514fcf7fb722e1194e086a5aa98159780502b217d616fd5bb450c02a6152253b7a8957278f35e3a01aabdd446a54f376" target="_blank"><strong>Facchin, Gianella&nbsp;</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Journal of Biological Inorganic Chemistry, 2022]]></dcterms:source>
    <dcterms:publisher><![CDATA[Springer]]></dcterms:publisher>
    <dcterms:date><![CDATA[2022]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><span><strong>Informaci&oacute;n sobre Derechos de Autor</strong></span></p>
<p><span>(Por favor lea este aviso antes de abrir los documentos u objetos)</span></p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho de autor</strong><span>&nbsp;sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</span></p>
<p><strong>ADVERTENCIA:</strong><span>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</span></p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[10.1007/s00775-022-01938-3]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/5267">
    <dcterms:title><![CDATA[<strong>Development of copper(II)-diimine-iminodiacetate mixed ligand complexes as potential antitumor agents</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[ANTINEOPLASICOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[COMPLEJOS DE COBRE]]></dcterms:subject>
    <dcterms:subject><![CDATA[ACTIVIDAD CITOTOXICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2018]]></dcterms:subject>
    <dcterms:abstract><![CDATA[In order to seek for new compounds with antitumor activity, our research group is focused on copper complexes with mixed ligands. This work presents the synthesis and characterization of eight compounds with general formula [Cu(iminodiacetate)(diimine)(H2O)x], with x = 0 or 1, and their cytotoxic activities against tumor cells. The chosen diimine ligands were: 2,2́-dipyridil-amine (bam), 2,2́-bipyridine (bipy), 4,4́-dimethyl-2,2́-bipyridine (dmb), 1,10-phenanthroline (phen), 4-methyl-1,10-phenanthroline (4met-phen), 5-nitro-1,10-phenanthroline (5nitro-phen), neocuproine (neo) and bathophenanthroline (batho). Compounds were characterized in solid state using FT-IR, TGA, DSC and single crystal X-ray diffraction analyses by which five new crystal structures were determined. Common features of the coordination scheme include fac-NO + O isomerism of the iminodiacetate (ida) ligand, except for the complex with neo where the ida presents mer-NO2 isomerism. The diimine ligand completes the equatorial plane for the facial isomers, with different degrees of distortion in the octahedral or square-based pyramid geometry depending on the diimine ligand, whereas the neo is perpendicular to the equatorial plane in the latter. Studies in solution, using EPR, UV&ndash;Vis spectroscopy and conductimetry, showed that the copper coordination observed in solid state is retained except for the batho complex. DNA interaction studies evidenced that the complexes bind to this biomolecule, inducing different conformational changes. Biological experiments evidenced that all complexes induce cell death in the cell line MDA-MD-231 (metastasic breast cancer line). [Cu(ida)(neo)] and [Cu(ida)(batho)] presented the highest activity. Taken all these data together we propose that [Cu(ida)(neo)] and [Cu(ida)(batho)] are good candidates for further studies in vitro and in vivo.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Alvarez, Natalia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Mendes, Luis F. S.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Kramer, M. Gabriela</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=1be7431d37af92df16867e8519adf042" target="_blank"><strong>Torre, Mar&iacute;a H.</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Costa Filho, Antonio J.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Ellena, Javier</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Facchin, Gianella.</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Inorganica Chimica Acta v. 483, 2018. -- p. 61-70]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2018]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong> La legislaci&oacute;n uruguaya protege el derecho</strong> de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1016/j.ica.2018.07.052]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/4814">
    <dcterms:title><![CDATA[<strong>Synthesis, structural characterization and cytotoxic activity against tumor cells of heteroleptic copper (I) complexes with aromatic diimines and phosphines</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[NEOPLASMA]]></dcterms:subject>
    <dcterms:subject><![CDATA[COBRE]]></dcterms:subject>
    <dcterms:subject><![CDATA[COMPLEJOS DE COBRE]]></dcterms:subject>
    <dcterms:subject><![CDATA[ACTIVIDAD CITOTOXICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2017]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Copper coordination complexes are increasingly recognized as potential drugs for therapeutic use in various diseases, especially in cancer. In an attempt to find new leaders for the development of antitumor Cu compounds, heteroleptic Cu(I) complexes with triphenylphosphine (PPh3) and dimethylbipyridine (dmbpy), phenanthroline (phen) or neocuproine (neo) were prepared and characterized. The compounds [CuCl(dmbpy)(PPh3)] (1), [CuCl(phen)(PPh3)]&sdot;0,25H2O (2) and [CuCl(neo)(PPh3)] (3) were obtained. The crystal structures of compounds 2 and 3 were determined. In both complexes, the Cu(I) centre presents distorted tetrahedral coordination. All complexes present cytotoxic activity, against tumor cell lines, being more active than Cisplatin, with IC50 in the low micromolar range. This activity augments in the order 1 &lt; 2 &lt; 3, following the same order as the lipophilicity.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Alvarez, Natalia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Noble, Carolina</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=1be7431d37af92df16867e8519adf042" target="_blank"><strong>Torre, Mar&iacute;a H.</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=37cace18c8d1da50d33d6bd4f8f1a607" target="_blank"><strong>Kremer, Eduardo.</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Ellena, Javier</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Peres de Araujo, Marcio</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Costa Filho, Antonio J</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Mendes, Luis Felipe</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Kramer, Gabriela M.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=5df591c19cc13f11564074d135cd4838" target="_blank"><strong>Facchin, Gianella</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Inorganica Chimica Acta v. 466, 2017. -- p. 559-564]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2017]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong> La legislaci&oacute;n uruguaya protege el derecho</strong> de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1016/j.ica.2017.06.050]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/2629">
    <dcterms:title><![CDATA[<strong>Palladium (II) complexes of 2-benzoylpyridine derived thiosemicarbazones : spectral characterization.</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[TIOSEMICARBAZONAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ESPECTROSCOPIA]]></dcterms:subject>
    <dcterms:subject><![CDATA[ACTIVIDAD CITOTOXICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2005]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Palladium(II) complexes of 2-benzoylpyridine thiosemicarbazone (H2Bz4DH) and its N(4)-methyl (H2Bz4M) and N(4)-phenyl (H2Bz4Ph) derivatives were obtained and fully characterized. [Pd(2Bz4DH)Cl] (1) crystallizes in the monoclinic space group P21/c with a = 11.671(1), b = 10.405(1), c = 13.124(1), b = 115.60(1) and Z = 4; [Pd(2Bz4M)Cl] (2) in the monoclinic space group P21/c with a = 9.695(1), b = 15.044(1), c = 10.718(1) A ˚ , b = 105.38(1) and Z = 4 and [Pd(2Bz4Ph)Cl] (3) in the triclinic space group P1 with a = 9.389(1), b = 13.629(1), c = 15.218(1) A ˚ , a = 70.25(1), b = 73.46(1), c = 83.57(1) and two independent molecules per asymmetric unit (Z = 4). All complexes show a quite similar planar fourfold environment around palladium(II). A negatively charged organic molecule acts as a tridentate ligand and binds to the metal through the pyridine nitrogen, the imine nitrogen and the sulfur atom. A chloride ion occupies the fourth coordination site. The planar complexes stack nearly parallel to one another in the lattice conforming a layered crystal structure. The cytotoxic activity of the thiosemicarbazones and their metal complexes was tested against the MCF-7, TK-10 and UACC-62 human tumor cell lines. The ligands exhibit lower values of GI50 and LC50 than the complexes, H2Bz4Ph being the most active with GI50 &lt; 0.003 lM; LC50 = 13.4 lM; GI50 = 9.3 lM, LC50 = 12.9 lM; GI50 &lt; 0.003, LC50 = 13.8 lM in the MCF-7, TK-10 and UACC-62 cell lines, respectively. Among the complexes, [Pd(2Bz4Ph)Cl] (3) exhibited the lowest values of GI50 in the three studied cell lines.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<a><strong>Rebolledo, Anayive P</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=f6108a739a086869ed201d4233fbfa4d"><strong>Vieites, Marisol</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=2ff5755f42707a83e7aea75299e5667c"><strong>Gambino, Dinorah</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Piro, Oscar E</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Castellano, Eduardo E</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Zani, Carlos L</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Souza Fagundes, Elaine M</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Teixeira, L</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Batista, Alzir A</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Beraldo, Helo&iacute;sa</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Journal of Inorganic Biochemistry v. 99, no. 3, 2005. -- p. 698-706]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2005]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes</p>
<p>(LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA</strong> - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>
<p>&nbsp;</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[doi:10.1016/j.jinorgbio.2004.11.022]]></dcterms:identifier>
</rdf:Description></rdf:RDF>
